The role of the topical nasal decongestant oxymetazoline as a novel therapeutic option for post‐acne erythema: A split‐face, double‐blind, randomized, placebo‐controlled trial.

MLA

Washrawirul, Chanudda, et al. “The Role of the Topical Nasal Decongestant Oxymetazoline as a Novel Therapeutic Option for Post‐acne Erythema: A Split‐face, Double‐blind, Randomized, Placebo‐controlled Trial.” Journal of Dermatology, vol. 50, no. 6, June 2023, pp. 739–45. EBSCOhost, https://doi.org/10.1111/1346-8138.16749.

APA

Washrawirul, C., Puaratana, arunkon, T., Chongpison, Y., Noppakun, N., Asawanonda, P., & Kumtornrut, C. (2023). The role of the topical nasal decongestant oxymetazoline as a novel therapeutic option for post‐acne erythema: A split‐face, double‐blind, randomized, placebo‐controlled trial. Journal of Dermatology, 50(6), 739–745. https://doi.org/10.1111/1346-8138.16749

Chicago

Washrawirul, Chanudda, arunkon, Thanaporn Puaratana, Yuda Chongpison, Nopadon Noppakun, Pravit Asawanonda, and Chanat Kumtornrut. 2023. “The Role of the Topical Nasal Decongestant Oxymetazoline as a Novel Therapeutic Option for Post‐acne Erythema: A Split‐face, Double‐blind, Randomized, Placebo‐controlled Trial.” Journal of Dermatology 50 (6): 739–45. doi:10.1111/1346-8138.16749.